By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.
Clinical Trial Design & Key Results
| Study Parameter | Detail |
|---|---|
| Trial Names | B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820) |
| Phase | Phase III |
| Treatment Duration | 6-month course |
| Primary Endpoint | Functional cure rate (HBsAg loss with undetectable HBV DNA) |
| Statistical Significance | p<0.001 for primary endpoint |
Pooled Analysis Results
| Patient Population | Functional Cure Rate | Statistical Significance |
|---|---|---|
| Overall Population (HBsAg ≤3000 IU/ml) | 19% | p<0.001 |
| Subgroup Analysis (Baseline HBsAg ≤1000 IU/ml) | 26% | p<0.001 |
Drug Mechanism & Innovation
- Molecule Type: Triple-mechanism antisense oligonucleotide (ASO)
- Mechanisms of Action:
- Reduces HBV-related RNA and viral protein production
- Lowers blood levels of hepatitis B surface antigen (HBsAg)
- Stimulates immune system for durable response
- Therapeutic Goal: Functional cure (sustained HBsAg loss after treatment cessation)
- Safety Profile: Acceptable safety and tolerability across both Phase III trials
Market Significance & Therapeutic Impact
- Unmet Medical Need: Current CHB treatments rarely achieve functional cure; most patients require lifelong therapy
- Clinical Breakthrough: 19-26% functional cure rates represent substantial improvement over existing standard of care (<1-3% cure rates)
- Patient Stratification: Higher efficacy in patients with lower baseline HBsAg (≤1000 IU/ml) enables targeted treatment approach
- Global Burden: Addresses critical need in hepatitis B-endemic regions affecting 296 million people worldwide
Strategic Partnership Dynamics
| Aspect | Sino Biopharmaceutical | GSK |
|---|---|---|
| Development Role | Co-development through CTTQ subsidiary | Co-development partner |
| Geographic Focus | Strong presence in China and Asia-Pacific | Global commercial infrastructure |
| Commercial Rights | Details not disclosed in announcement | Likely global rights with regional partnerships |
| Pipeline Integration | Expands Sino Bio’s innovative antiviral portfolio | Strengthens GSK’s specialty medicines pipeline |
Competitive Landscape in Hepatitis B Functional Cure
| Approach | Leading Companies | Current Status | Bepirovirsen Advantage |
|---|---|---|---|
| ASO Therapy | Ionis/GSK (bepirovirsen) | Phase III positive | First to demonstrate 19%+ functional cure |
| siRNA Therapies | Arrowhead, Janssen, Vir | Phase II | Lower reported cure rates |
| Capsid Inhibitors | Assembly Biosciences, Roche | Phase II | Primarily suppressive, limited cure data |
| Therapeutic Vaccines | Gilead, Transgene | Early development | Immune stimulation component already integrated |
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for bepirovirsen. Actual results may differ due to risks including final regulatory approvals, market competition, and evolving treatment guidelines for chronic hepatitis B.-Fineline Info & Tech